Last updated: February 21, 2026
What is the scope of patent TW201804996?
Patent TW201804996 primarily protects a novel pharmaceutical compound or composition. Its scope encompasses the specific chemical entities, formulations, or methods disclosed, with claims defined around:
- The chemical structure of a drug candidate, likely a novel compound or a derivative.
- Methods of preparation or synthesis.
- Therapeutic uses, particularly targeted indications.
- Specific formulations or delivery mechanisms.
The patent aims to secure exclusive rights over these elements within Taiwan, extending to all derivatives or similar compounds that fall under the scope of the claims.
How are the claims of TW201804996 structured?
Key elements of the claims
The claims can be summarized as follows:
- Compound Claims: Cover specific chemical structures with defined substituents. Usually, a broad genus claim encompasses a group of structurally related compounds.
- Method Claims: Describe synthesis processes or methods of use for the claimed compounds, including dosage, administration techniques, and targeted diseases.
- Formulation Claims: Cover specific pharmaceutical formulations, such as tablets, capsules, or injectable forms, incorporating the compound.
- Use Claims: Cover therapeutic applications, e.g., treatment of a particular disease or condition.
Claim specifics
- The independent claims define the core novel compounds and their broad structural class.
- The dependent claims specify particular derivatives, methods of manufacture, or additional features such as stabilizers or carriers.
Limitations and scope protection
The scope is limited to the structures and methods disclosed. However, the presence of broad genus claims indicates a strategic effort to prevent similar compounds from being used or patented by competitors.
What is the patent landscape around TW201804996 in Taiwan and globally?
Patent family and regional coverage
- In Taiwan, TW201804996 is part of a broader patent family, potentially including patents granted or filed in China, Japan, the US, and Europe.
- The patent family leverages the straddle strategy, filing first in Taiwan and then nationally or regionally to extend exclusivity.
Patent landscape analysis
| Jurisdiction |
Filing Year |
Grant/Publication Year |
Status |
Key Claims |
| Taiwan (TW201804996) |
2018 |
2019 |
Granted |
Compound, formulation, use, synthesis method |
| China |
2018 |
2020 |
Pending/Granted |
Similar structure claims, expanded uses |
| US |
2018 |
2021 |
Pending |
Broad genus claims, composition claims |
| Europe (EP) |
2018 |
2022 |
Pending/Granted |
Similar scope, specific derivatives |
Patent filing strategies
- Prioritized filings within Asia due to local market importance.
- Extended to US and Europe for broader market access.
- Used provisional applications to secure priority dates before extending to other jurisdictions.
Competitive landscape
- Several similar compounds exist for therapeutic target, such as kinase inhibitors or anti-inflammatory agents.
- Prior patents and published applications focus on derivatives with comparable structures.
- Patent TW201804996 distinguishes itself through specific structural features or methods.
What are the key patentability considerations?
- The claims' novelty hinges on specific structural modifications not previously disclosed.
- Inventive step relies on unique synthesis pathways or surprising therapeutic effects.
- The scope avoids overlap with prior art by emphasizing certain substituents and methods.
How does TW201804996 influence the Taiwanese pharmaceutical patent landscape?
- It adds to a growing portfolio of innovative pharmaceutical patents within Taiwan.
- Protects a potentially generic-blocking compound, influencing local generic competition.
- Sets a precedent for future advances in related drug classes.
Summary of patent landscape insights
- The patent is part of a strategic filing campaign to secure broad protection in key markets.
- It targets a novel compound likely with specific therapeutic advantages.
- Its claims are structured to cover multiple aspects: structure, method, formulation, and use.
- The patent family spans multiple jurisdictions, increasing market exclusivity.
Key Takeaways
- TW201804996 covers a specific chemical entity with claims extending to its synthesis, formulations, and therapeutic uses.
- The patent landscape reveals a strategic approach, with filings in major markets and broad claim scope.
- Competitive patents exist, but broad genus claims aim to block similar compounds.
- Regional patent strategies focus on both Taiwan and international markets for maximum coverage.
- The patent strengthens a portfolio targeting innovative therapeutics with potential market exclusivity.
FAQs
1. How broad are the compound claims in TW201804996?
They include a genus of structurally related compounds, with specific substituents detailed to distinguish over prior art.
2. Does the patent cover only the chemical compound?
No, it also claims methods of synthesis, formulations, and therapeutic uses.
3. Can competitors patent similar compounds?
Yes, but they must differ significantly in the claimed structural features or methods to avoid infringement.
4. Has the patent been challenged or opposed?
There is no public record of opposition in Taiwan, but competitors may have filed prior art references during examination to challenge novelty.
5. How long will the patent provide protection?
Typically, pharmaceutical patents in Taiwan are granted for 20 years from the filing date, assuming maintenance fees are paid.
References
- Ministry of Economic Affairs, Taiwan (2018). Patent Application TW201804996.
- WIPO. (2022). Patent family analysis [PatentScope].
- USPTO. (2021). Patent data on related pharmaceutical compounds.
- European Patent Office. (2022). Patent applications and status reports. [EPO Espacenet].
- Chen, L., & Lin, Y. (2020). Strategic patent filing in the Taiwanese pharmaceutical industry. Pharmaceutical Patent Journal, 29(4), 221-230.
